Quantcast

Industry news that matters to you.  Learn more

Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing

Genomic Health, Inc. (Nasdaq: GHDX) and OncoMed Pharmaceuticals, Inc. (OncoMed) today announced a strategic alliance to use Next Generation Sequencing (NGS) to identify biomarkers that can be applied to the clinical development of OncoMed’s novel antibody cancer therapeutics.

TCGA Study Brings Ovarian Cancer Patients Closer to Personalized Medicine

In the June 30 issue of Nature, researchers from The Cancer Genome Atlas (TCGA) Research Network provide a large-scale integrative report on genetic mutations and pathways that distinguish the most common and aggressive type of ovarian cancer from other types of ovarian cancer as well as from other solid tumors. The disease is not defined by one or few cancer-driving genes but rather numerous mutations that individually occur in only a small number of cases. Given the degree of genomic disarray, the study results suggest that genomic structural variation is the driver of ovarian cancer. The findings may be helpful in guiding physicians to choose experimental treatments that are most likely to target molecular alterations effectively in patients with high-grade serous ovarian adenocarcinoma.